Diurnal Secretion Profiles of Growth Hormone, Thyrotrophin and Prolactin in Parkinson's Disease
Diurnal Secretion Profiles of Growth Hormone, Thyrotrophin and Prolactin in Parkinson's Disease
复制标题
DOI：
10.1111/j.1365-2826.2011.02134.x
复制
发表时间：
2011-06-01
影响因子：
3.2
通讯作者：
Roos, R. A. C.
中科院分区：
文献类型：
--
作者：
Aziz, N. A.;Pijl, H.;Roos, R. A. C.
最近，在帕金森病（PD）患者的下丘脑中发现下丘脑分泌素和黑色素浓缩激素（MCH）神经元大量丢失。由于下丘脑分泌素和 MCH 在调节睡眠、能量稳态和自主神经功能中发挥着关键作用，部分通过调节生长激素、促甲状腺激素和泌乳激素轴，神经内分泌失调可能导致 PD 的一些非运动特征。在 8 名未接受药物治疗的新发 PD 患者和 8 名年龄、性别和体重指数匹配的对照组中，我们在 24 小时内每 10 分钟测量生长激素 (GH)、促甲状腺激素 (TSH) 和催乳素的血清水平。应用自动解卷积、余弦和近似熵分析来量化 GH、TSH 和催乳素分泌率、昼夜节律以及激素释放的规律性。整个晚上的睡眠情况都被记录下来。 GH 的总 24 小时分泌量（191 +/- 31 与 130 +/- 39 mU/l/24 小时）、TSH（38 +/- 9 与 36 +/- 2 mU/l/24 小时）和催乳素（102 +/- 14 与 116 +/- 17 μg/l/24 小时）及其昼夜节律性和释放规律性均不显着。 PD患者和对照组之间的差异 （所有 P >= 0.12）。 PD 患者中胰岛素样生长因子 1 的空腹水平也没有改变。然而，与对照组相比，PD 患者的游离甲状腺素 (T(4)) 水平显着升高（16.19 +/- 0.80 vs 13.88 +/- 0.40 pmol/l；P = 0.031）。在PD患者中，催乳素水平与病程相关（r = 0.76，P = 0.028），而GH（r = -0.91，P = 0.002）和游离T（4）（r = -0.71，P = 0.050）水平与身体脂肪含量呈负相关。除了游离 T(4) 水平轻度升高外，我们没有发现早期 PD 患者的生长激素轴、促甲状腺轴和泌乳轴活性发生改变的迹象。
Recently, a massive loss of both hypocretin and melanin-concentrating hormone (MCH) neurones was found in the hypothalamus of Parkinson's disease (PD) patients. Because both hypocretin and MCH play a key role in the regulation of sleep, energy homeostasis and autonomic function, partly by modulation of the somatotrophic, thyrotrophic and lactotrophic axes, neuroendocrine dysregulation may contribute to some of the non-motor features of PD. In eight de novo, medication-free PD patients and eight age-, sex- and body mass index-matched controls, we measured serum levels of growth hormone (GH), thyroid-stimulating hormone (TSH) and prolactin every 10 min for 24 h. Auto-deconvolution, cosinor and approximate entropy analysis were applied to quantify GH, TSH and prolactin secretion rates, diurnal rhythmicity, as well as regularity of hormone release. Sleep was polygraphically-recorded throughout the night. Total 24-h secretion of GH (191 +/- 31 versus 130 +/- 39 mU/l/24 h), TSH (38 +/- 9 versus 36 +/- 2 mU/l/24 h) and prolactin (102 +/- 14 versus 116 +/- 17 mu g/l/24 h), as well as their diurnal rhythmicity and regularity of release, were not significantly different between PD patients and controls (all P >= 0.12). Fasting levels of insulin-like growth factor-1 were also unaltered in PD patients. However, free thyroxine (T(4)) levels were significantly higher in PD patients compared to controls (16.19 +/- 0.80 versus 13.88 +/- 0.40 pmol/l; P = 0.031). In PD patients, prolactin levels were related to disease duration (r = 0.76, P = 0.028), whereas both GH (r = -0.91, P = 0.002) and free T(4) (r = -0.71, P = 0.050) levels correlated inversely with body fat content. Apart from a mild increase in free T(4) levels, we found no indications for altered somatotrophic, thyrotrophic and lactotrophic axes activity in early-stage PD patients.